Comparing Two Methods to Follow Patients With Pancreatic Cysts
a study on Pancreatic Cancer Pancreatic Cyst Pancreatic Neoplasms
Summary
- Eligibility
- for people ages 50-75 (full criteria)
- Location
- at Encinitas, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Rebekah R. White
Description
Summary
The purpose of this study is to compare the two approaches for monitoring pancreatic cysts. The study doctors want to compare more frequent monitoring vs less frequent monitoring in order to learn which monitoring method leads to better outcome for patients with pancreatic cysts.
Official Title
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs
Details
PRIMARY OBJECTIVES:
- To compare the rates of unfavorable clinical outcomes in the two arms.
SECONDARY OBJECTIVES:
- To compare rates of major surgical morbidity and/or mortality between arms. II. To compare pancreatic cancer incidence and all-cause mortality across arms. III. Compare institutional (direct) costs. IV. Compare healthcare utilization of imaging, invasive testing, surgical, and other procedures across the two surveillance arms.
- Compare patient (out-of-pocket and other indirect) costs. VI. Describe diagnostic test and treatment pathways by arm. VII. Compare patient reports of quality of life (QOL), situational anxiety. VIII. Compare patient report of financial distress. IX. Compare rates of non-adherence by arm assignment. X. To evaluate and compare the predictive performance of known and future biomarkers for dysplasia or cancer.
EXPLORATORY OBJECTIVE:
- To evaluate and compare the predictive accuracy of known and future radiomic markers for dysplasia and pancreatic cancer.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A (LOW INTENSITY SURVEILLANCE): Patients undergo magnetic resonance imaging (MRI) or computed tomography (CT) at the beginning of the trial and again in 1 year. Following the first year, patients with no abnormalities repeat MRI or CT every 2 years. Patients with positive imaging features on MRI and CT at 1 or 2 years and with negative endoscopic ultrasound (EUS), repeat MRI or CT in 1 year. Patients with negative imaging repeat MRI or CT in 2 years.
ARM B (HIGH INTENSITY SURVEILLANCE): Patients undergo MRI or CT. Patients with 1-2 cm cyst undergo MRI or CT every 6 months for 1 year, then every 12 months for 2 years, and then every 24 months thereafter. Patients with 2-3 cm cyst undergo EUS within 6 months, and if EUS is negative, patients repeat MRI or CT in 1 year. If second EUS is negative, patients undergo alternate MRI or CT and EUS every 12 months. Patients with cyst > 3 cm undergo EUS within 6 months, and if EUS is negative, patients undergo alternate MRI or CT with EUS every 3-6 months.
After completion of imaging procedures, patients are followed up for 5 years from the date of registration .
Keywords
Pancreatic Carcinoma, Pancreatic Neoplasms, Pancreatic Cyst, Computed Tomography, Endoscopic Ultrasound, Magnetic Resonance Imaging, Quality-of-Life Assessment
Eligibility
For people ages 50-75
- Patient must be ≥ 50 years and ≤ 75 years of age.
- Patient must not have acute pancreatitis or a history of chronic pancreatitis.
- Patient must have received a CT, MRI, or EUS within 6 months prior to randomization that revealed one or more ≥ 1 cm pancreatic cyst (s).
- Patients of childbearing potential must not be known to be pregnant.
- Patient must not have a prior diagnosis of pancreatic malignancy of any type.
- Patient must not have a history of pancreatic resection.
- Patients with only pancreatic lesions without malignant risk (pancreatic pseudocyst or classic serous cystic lesion) are not eligible.
- Patient must not have a family history of pancreatic adenocarcinoma in one or more first degree relatives(biological parents, full siblings or children).
- Patient must not have pancreatic cyst morphology that would prompt immediate surgical consideration (enhancing mural nodule, solid component in cyst, pancreatic duct ≥10mm, cyst causing obstructive jaundice).
- Patient must not have a comorbid illness that precludes pancreatic cyst resection.
- Patient must not be participating in any form of pancreatic cyst surveillance.
Locations
- UC San Diego Health System - Encinitas
currently not accepting new patients, but might later
Encinitas California 92024 United States - UC San Diego Moores Cancer Center
accepting new patients
La Jolla California 92093 United States - UC San Diego Medical Center - Hillcrest
currently not accepting new patients, but might later
San Diego California 92103 United States - UCLA / Jonsson Comprehensive Cancer Center
accepting new patients
Los Angeles California 90095 United States
Lead Scientist at UCSD
- Rebekah R. White
Professor, Surgery, Vc-health Sciences-schools. Authored (or co-authored) 50 research publications
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- ECOG-ACRIN Cancer Research Group
- ID
- NCT04239573
- Study Type
- Interventional
- Participants
- Expecting 4606 study participants
- Last Updated
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study, which might include an external sponsor. Submitting your contact information does not obligate you to participate in research.
Thank you!
The study team should get back to you in a few business days.